Table 1 Baseline clinical characteristics of the study participants.
Variables | ICAS (n = 136) | ECAS (n = 45) | COAS (n = 73) | NCAS (n = 154) | F/χ2 | P |
---|---|---|---|---|---|---|
Age (years) | 63 ± 12 | 65 ± 11* | 66 ± 9.0* | 60 ± 13 | 1.006 | 0.469 |
Gender (male) | 80 (58.8%) | 33 (73.3%) | 49(67.1%) | 101(65.6%) | 3.744 | 0.291 |
Hypertension(n(%)) | 91 (66.9%) | 28(62.2%) | 52 (71.2%) | 93(60.4%) | 3.029 | 0.387 |
Diabetes (n (%)) | 37 (27.2%) | 15(33.3%) | 18 (24.7%) | 31(20.1%) | 3.985 | 0.263 |
Glycosylated hemoglobin(%) | 5.70 (5.20–7.20) | 5.80 (5.40–6.65) | 5.60 (5.20–6.85) | 5.70 (5.40–6.50) | 0.864 | 0.834 |
TC (mmol/L) | 5.01 ± 1.09* | 5.25 ± 0.97* | 5.23 ± 1.07* | 4.59 ± 1.22 | 7.772 | <0.001 |
TG (mmol/L) | 1.62 ± 0.97 | 1.64 ± 0.92 | 1.54 ± 0.83 | 1.73 ± 2.17 | 0.274 | 0.844 |
HDL-C (mmol/L) | 1.14 ± 0.30* | 1.15 ± 0.31 | 1.17 ± 0.33 | 1.24 ± 0.31 | 2.590 | 0.052 |
LDL-C (mmol/L) | 3.18 ± 1.00* | 3.33 ± 0.74* | 3.38 ± 0.87* | 2.71 ± 0.90 | 13.879 | <0.001 |
ApoA1 (g/L) | 1.11 ± 0.26* | 1.17 ± 0.23 | 1.10 ± 0.20* | 1.21 ± 0.26 | 5.635 | 0.001 |
ApoB (g/L) | 1.06 ± 0.22* | 1.09 ± 0.21* | 1.12 ± 0.21* | 0.88 ± 0.24 | 28.599 | <0.001 |
ApoB/ApoA1 | 1.00 ± 0.42* | 0.94 ± 0.19* | 1.05 ± 0.23* | 0.74 ± 0.22 | 25.408 | <0.001 |